DE60019106D1 - Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen - Google Patents
Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungenInfo
- Publication number
- DE60019106D1 DE60019106D1 DE60019106T DE60019106T DE60019106D1 DE 60019106 D1 DE60019106 D1 DE 60019106D1 DE 60019106 T DE60019106 T DE 60019106T DE 60019106 T DE60019106 T DE 60019106T DE 60019106 D1 DE60019106 D1 DE 60019106D1
- Authority
- DE
- Germany
- Prior art keywords
- disorders
- environment
- peptides
- behavioral disorders
- treating impaired
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Radiation-Therapy Devices (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14056399P | 1999-06-23 | 1999-06-23 | |
US140563 | 1999-06-23 | ||
PCT/EP2000/006259 WO2001000221A2 (en) | 1999-06-23 | 2000-06-22 | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60019106D1 true DE60019106D1 (de) | 2005-05-04 |
DE60019106T2 DE60019106T2 (de) | 2006-02-16 |
Family
ID=22491816
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60019106T Expired - Lifetime DE60019106T2 (de) | 1999-06-23 | 2000-06-22 | Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen |
DE60040878T Expired - Lifetime DE60040878D1 (de) | 1999-06-23 | 2000-06-22 | Zusammensetzungen zur Behandlung von beeinträchtigten zwischenmenschlischen Störungen und Verhaltenstörungen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60040878T Expired - Lifetime DE60040878D1 (de) | 1999-06-23 | 2000-06-22 | Zusammensetzungen zur Behandlung von beeinträchtigten zwischenmenschlischen Störungen und Verhaltenstörungen |
Country Status (14)
Country | Link |
---|---|
US (2) | US7387778B2 (de) |
EP (2) | EP1593387B1 (de) |
JP (1) | JP2003512302A (de) |
CN (1) | CN1189211C (de) |
AT (2) | ATE291927T1 (de) |
AU (1) | AU6154700A (de) |
CA (1) | CA2376935A1 (de) |
CY (1) | CY1108745T1 (de) |
DE (2) | DE60019106T2 (de) |
DK (2) | DK1593387T3 (de) |
ES (2) | ES2315753T3 (de) |
NZ (1) | NZ516477A (de) |
PT (2) | PT1593387E (de) |
WO (1) | WO2001000221A2 (de) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
AU6154700A (en) | 1999-06-23 | 2001-01-31 | Centre National De La Recherche Scientifique (C.N.R.S.) | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
ES2235806T3 (es) * | 2000-12-22 | 2005-07-16 | Institut Pasteur | Procedimiento de seleccion de moleculas ligando que se unen especificamente al sitio de union nep para el prentapeptido qhnpr. |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
SI1594517T1 (sl) | 2003-01-28 | 2007-10-31 | Microbia Inc | Sestavki za zdravljenje gastrointestinalnih motenj |
EP1577320B1 (de) | 2004-03-19 | 2012-07-18 | Institut Pasteur | Von humanen BPLP Proteinen abgeleitete Peptide, deren kodierende Polynukleotide und Antikörper gegen besagte Peptide |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EA020466B1 (ru) | 2007-06-04 | 2014-11-28 | Синерджи Фармасьютикалз Инк. | Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний |
RU2542365C2 (ru) | 2008-04-07 | 2015-02-20 | Энститю Пастёр | Производные опиорфинного пептида как потенциальные ингибиторы эктопептидаз, участвующих в деградации энкефалинов |
FR2931362B1 (fr) | 2008-05-26 | 2017-08-18 | Pasteur Institut | L'opiorphine pour une utilisation en tant que psychostimulant. |
CA2726917C (en) | 2008-06-04 | 2018-06-26 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
CA2645452A1 (en) * | 2008-11-28 | 2010-05-28 | Institut Pasteur | Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker |
CA2994066A1 (en) | 2008-12-03 | 2010-06-10 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase c agonists and methods of use |
DE102009039655B3 (de) | 2009-09-02 | 2011-03-31 | ITT Mfg. Enterprises, Inc., Wilmington | UV-Desinfektionseinrichtung für Abwasser und Trinkwasser mit einer Reinigungsvorrichtung |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2012118972A2 (en) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Process of preparing guanylate cyclase c agonists |
EP2970384A1 (de) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonisten der guanylatcyclase und deren verwendungen |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
CN113388007A (zh) | 2013-06-05 | 2021-09-14 | 博士医疗爱尔兰有限公司 | 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法 |
GB201607814D0 (en) | 2016-05-04 | 2016-06-15 | 5D Health Prot Group Ltd | Anti-microbial compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8327966D0 (en) * | 1983-10-19 | 1983-11-23 | Nyegaard & Co As | Chemical compounds |
FR2637600B1 (fr) * | 1988-10-11 | 1992-03-06 | Pasteur Institut | Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques |
US5589189A (en) * | 1994-09-14 | 1996-12-31 | Nexstar Pharmaceuticals, Inc. | Liposome dispersion |
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
KR100353014B1 (ko) | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
US6455564B1 (en) * | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
AU6154700A (en) | 1999-06-23 | 2001-01-31 | Centre National De La Recherche Scientifique (C.N.R.S.) | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
ES2235806T3 (es) | 2000-12-22 | 2005-07-16 | Institut Pasteur | Procedimiento de seleccion de moleculas ligando que se unen especificamente al sitio de union nep para el prentapeptido qhnpr. |
-
2000
- 2000-06-22 AU AU61547/00A patent/AU6154700A/en not_active Abandoned
- 2000-06-22 DE DE60019106T patent/DE60019106T2/de not_active Expired - Lifetime
- 2000-06-22 DE DE60040878T patent/DE60040878D1/de not_active Expired - Lifetime
- 2000-06-22 ES ES05006494T patent/ES2315753T3/es not_active Expired - Lifetime
- 2000-06-22 CA CA002376935A patent/CA2376935A1/en not_active Abandoned
- 2000-06-22 PT PT05006494T patent/PT1593387E/pt unknown
- 2000-06-22 EP EP05006494A patent/EP1593387B1/de not_active Expired - Lifetime
- 2000-06-22 EP EP00947924A patent/EP1185294B1/de not_active Expired - Lifetime
- 2000-06-22 WO PCT/EP2000/006259 patent/WO2001000221A2/en active IP Right Grant
- 2000-06-22 DK DK05006494T patent/DK1593387T3/da active
- 2000-06-22 PT PT00947924T patent/PT1185294E/pt unknown
- 2000-06-22 ES ES00947924T patent/ES2238299T3/es not_active Expired - Lifetime
- 2000-06-22 AT AT00947924T patent/ATE291927T1/de active
- 2000-06-22 CN CNB008092958A patent/CN1189211C/zh not_active Expired - Fee Related
- 2000-06-22 JP JP2001505930A patent/JP2003512302A/ja active Pending
- 2000-06-22 NZ NZ516477A patent/NZ516477A/xx not_active IP Right Cessation
- 2000-06-22 AT AT05006494T patent/ATE414529T1/de active
- 2000-06-22 DK DK00947924T patent/DK1185294T3/da active
-
2001
- 2001-12-21 US US10/024,535 patent/US7387778B2/en not_active Expired - Fee Related
-
2002
- 2002-12-10 US US10/315,445 patent/US20030186870A1/en not_active Abandoned
-
2009
- 2009-01-16 CY CY20091100058T patent/CY1108745T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
PT1185294E (pt) | 2005-08-31 |
ES2238299T3 (es) | 2005-09-01 |
JP2003512302A (ja) | 2003-04-02 |
WO2001000221A2 (en) | 2001-01-04 |
US7387778B2 (en) | 2008-06-17 |
DE60019106T2 (de) | 2006-02-16 |
WO2001000221A3 (en) | 2001-05-03 |
ATE414529T1 (de) | 2008-12-15 |
NZ516477A (en) | 2004-02-27 |
DK1593387T3 (da) | 2009-03-02 |
EP1593387B1 (de) | 2008-11-19 |
EP1185294A2 (de) | 2002-03-13 |
AU6154700A (en) | 2001-01-31 |
CY1108745T1 (el) | 2014-04-09 |
PT1593387E (pt) | 2009-03-18 |
CN1356906A (zh) | 2002-07-03 |
EP1593387A1 (de) | 2005-11-09 |
ES2315753T3 (es) | 2009-04-01 |
CN1189211C (zh) | 2005-02-16 |
CA2376935A1 (en) | 2001-01-04 |
US20030186870A1 (en) | 2003-10-02 |
US20030078200A1 (en) | 2003-04-24 |
ATE291927T1 (de) | 2005-04-15 |
DK1185294T3 (da) | 2005-08-01 |
DE60040878D1 (de) | 2009-01-02 |
EP1185294B1 (de) | 2005-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60019106D1 (de) | Peptide zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen | |
WO2004019884A3 (en) | Agents and methods for enhancing bone formation | |
ATE430193T1 (de) | Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen | |
ATE399553T1 (de) | Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen | |
ATE510542T1 (de) | Noribogain zur behandlung von schmerzen und drogenabhängigkeit | |
HRP20020593B1 (en) | Brain, spinal and nerve injury treatment | |
ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
DE60333857D1 (de) | Oxytocin zur Behandlung von Autismus und Asperger-Syndrom | |
DE60227658D1 (de) | Verfahren zur behandlung neurodegenerativer, psychiatrischer und anderer störungen mit deacetylaseinhibitoren | |
ATE144420T1 (de) | Verwendung von riluzol zur behandlung von parkinson und den parkinson-syndromen | |
WO2005020928A3 (en) | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins | |
BR0015698A (pt) | Composições e métodos para tratamento de doenças alérgicas | |
DE69929464D1 (de) | Zyklische polyamine zur behandlung der thrombozytopenie | |
ATE234089T1 (de) | Zubereitungen enthaltend sclareol und sclareolide zur behandlung mikrobieller infektionen | |
DE60008143D1 (de) | Lipoxin-a4 und deren analoge zur behandlung von trockenen augen | |
DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
IL171384A (en) | Use of slurp-1 in the preparation of medicaments for the treatment of neurological disorders | |
ATE355054T1 (de) | Verfahren und verbindungen zur behandlung der depression | |
ATE541565T1 (de) | Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus | |
DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
DE60018704D1 (de) | Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen | |
DE60142786D1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
MXPA04010816A (es) | Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares. | |
ATE548048T1 (de) | Oncomodulin zur behandlung von neurologishen erkrankungen | |
ATE498397T1 (de) | Verwendung von isorhamnetin zur behandlung von depressiven verstimmungen und erkrankungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |